KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene

par Roberts, Melyssa S., Anstine, Lindsey J., Finke, Viviane S., Bryson, Benjamin L., Webb, Bryan M., Weber-Bonk, Kristen L., Seachrist, Darcie D., Majmudar, Parth R., Keri, Ruth A.
Publié dans Breast Cancer Res (2020)

LIN9 and NEK2 are core regulators of mitotic fidelity that can be therapeutically targeted to overcome taxane resistance

par Roberts, Melyssa S., Sahni, Jennifer M., Schrock, Morgan S., Piemonte, Katrina M., Weber-Bonk, Kristen L., Seachrist, Darcie D., Avril, Stefanie, Anstine, Lindsey J., Singh, Salendra, Sizemore, Steven T., Varadan, Vinay, Summers, Matthew K., Keri, Ruth A.
Publié dans Cancer Res (2020)